Clinical Trial · NCT06738680

PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1

Overview

Lung cancer is the leading cause of cancer deaths worldwide. Revolution of chemo-immunotherapy (CT-IO) in first-line of metastatic non-small-cell lung cancers (NSCLC) without actionable genomic alterations (AGAs) has dramatically improved prognosis, providing long response to a subset of patients. Because of a highly heterogeneous disease, majority of patients do not show long term benefit. Long axial field of view positron emission tomography (LAFOV-PET) scanner is a new emerging system allowing dynamic whole-body imaging with higher sensitivity, representing unique opportunity for oncological applications. The aim of this study is to determine if LAFOV-PET imaging biomarkers could early predict response to CT-IO in NSCLC.

Sponsor

University Hospital, Brest

Contacts

Margaux GEIER (STUDY_DIRECTOR)

Margaux GEIER (CONTACT)

margaux.geier@chu-brest.fr

+33230338030

Ronan ABGRAL (CONTACT)

ronan.abgral@chu-brest.fr

+33298223069

ClinicalTrials.gov

NCT06738680

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Eligible for first-line chemo-immunotherapy (anti-PD-1)
Written Non-objection
With advanced, non-operable, non-radiatable or metastatic NSCLC
Treatment-naïve patients
* Adult patients ≥ 18 years

Exclusion

Ineligible for first-line chemo-immunotherapy
Pregnancy or breast-feeding
Oncogenic addiction targetable in 1st line: EGFR, ALK, ROS1, RET
* Minor patients \<18 years
Other histology than NSCLC